0 167

Cited 41 times in

Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.

 H. C. Jeung  ;  S. Y. Rha  ;  W. I. Jang  ;  S. H. Noh  ;  H. C. Chung 
 British Journal of Surgery, Vol.89(4) : 460-466, 2002 
Journal Title
 British Journal of Surgery 
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/surgery* ; Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Child ; Child, Preschool ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Combined Modality Therapy/methods ; Disease-Free Survival ; Feasibility Studies ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Infant ; Infant, Newborn ; Middle Aged ; Neoplasm Staging/methods ; Palliative Care/methods* ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/surgery*
Background: The treatment options for the 10–20 per cent of patients with gastric cancer who present with peritoneal dissemination are extremely limited and no standard approach exists. Methods: The feasibility of using intraperitoneal chemotherapy to treat gastric cancer with intra-abdominal gross residual lesions after palliative gastrectomy with maximal cytoreduction was investigated. Early postoperative intraperitoneal chemotherapy started on the day of operation with 5-fluorouracil 500 mg/m2 and cisplatin 40 mg/m2 (days 1–3) over a 4-week interval. Results: Of the 53 patients enrolled between July 1994 and December 1998, 49 were eligible. The progression-free survival (PFS) was 7 months and the overall survival was 12 months. In multivariate analysis, performance status was the only significant defining factor for PFS (P = 0·009). The predominant toxicity was neutropenia and nausea/vomiting. The relative dose intensity of 5-fluorouracil and cisplatin was 89 and 63 per cent respectively. Conclusion: Performance status emerged as a major determining factor for prognosis and patient selection for early postoperative intraperitoneal chemotherapy in patients with advanced gastric cancer after maximally cytoreductive surgery.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
5. Research Institutes (연구소) > Cancer Metastasis Research Center (암전이연구센터) > 1. Journal Papers
Yonsei Authors
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.